Business Description
Lipigon Pharmaceuticals AB
ISIN : SE0015382072
Compare
Compare
Traded in other countries / regions
LPGO.Sweden9RP.Germany IPO Date
2021-03-10Description
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.85 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.53 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9.2 | |||||
| 3-Year EBITDA Growth Rate | 33.5 | |||||
| 3-Year EPS without NRI Growth Rate | 32.7 | |||||
| 3-Year FCF Growth Rate | 31.3 | |||||
| 3-Year Book Growth Rate | -39.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.07 | |||||
| 9-Day RSI | 49.9 | |||||
| 14-Day RSI | 47.45 | |||||
| 6-1 Month Momentum % | -39.64 | |||||
| 12-1 Month Momentum % | -43.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.51 | |||||
| Quick Ratio | 6.51 | |||||
| Cash Ratio | 6.19 | |||||
| Days Sales Outstanding | 122.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -116.1 | |||||
| Shareholder Yield % | -83.04 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -33.68 | |||||
| Net Margin % | -32.25 | |||||
| FCF Margin % | -56.9 | |||||
| ROE % | -25.61 | |||||
| ROA % | -19.89 | |||||
| ROIC % | -87.55 | |||||
| ROC (Joel Greenblatt) % | -233.98 | |||||
| ROCE % | -25.6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.82 | |||||
| PB Ratio | 1.24 | |||||
| Price-to-Tangible-Book | 1.01 | |||||
| EV-to-EBIT | -1 | |||||
| EV-to-EBITDA | -1.01 | |||||
| EV-to-Revenue | 0.32 | |||||
| EV-to-FCF | -0.38 | |||||
| Price-to-Net-Current-Asset-Value | 1.01 | |||||
| Price-to-Net-Cash | 2.01 | |||||
| Earnings Yield (Greenblatt) % | -100.6 | |||||
| FCF Yield % | -23.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lipigon Pharmaceuticals AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.406 | ||
| EPS (TTM) (€) | -0.014 | ||
| Beta | 1.17 | ||
| Volatility % | 102.09 | ||
| 14-Day RSI | 47.45 | ||
| 14-Day ATR (€) | 0.004423 | ||
| 20-Day SMA (€) | 0.021265 | ||
| 12-1 Month Momentum % | -43.02 | ||
| 52-Week Range (€) | 0.014 - 0.0622 | ||
| Shares Outstanding (Mil) | 126.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lipigon Pharmaceuticals AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lipigon Pharmaceuticals AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lipigon Pharmaceuticals AB Frequently Asked Questions
What is Lipigon Pharmaceuticals AB(STU:9RP)'s stock price today?
The current price of STU:9RP is €0.02. The 52 week high of STU:9RP is €0.06 and 52 week low is €0.01.
When is next earnings date of Lipigon Pharmaceuticals AB(STU:9RP)?
The next earnings date of Lipigon Pharmaceuticals AB(STU:9RP) is 2024-05-28.
Does Lipigon Pharmaceuticals AB(STU:9RP) pay dividends? If so, how much?
Lipigon Pharmaceuticals AB(STU:9RP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers